<?xml version="1.0" encoding="UTF-8"?><AQE.QER VERSION="2"><QUESTION QID="E-002425-19" AIDREF="AE-002425-19" LEG.VAL="WQ"><HEAD.Q><TI1><P.WQ>Question for written answer<NO.WQ QID="Q-E-002425-19">E-002425-19</NO.WQ></P.WQ><P.WQ>to the<DEST.WQ ORG="COM"> Commission</DEST.WQ></P.WQ></TI1><TI2><P.WQ>Rule 138</P.WQ><P.WQ><AUTHOR.WQ PERSID="28266">Sophia in 't Veld</AUTHOR.WQ><POL.GROUP GR="Renew">(Renew)</POL.GROUP></P.WQ></TI2><P.WQ><DATE.WQ DATE.DOC="20190724">(24 July 2019)</DATE.WQ></P.WQ></HEAD.Q><OBJ.Q OBJID="O-E-002425-19"><INT.OBJ.Q>Subject:</INT.OBJ.Q><TXT> EU cross-border healthcare measures</TXT></OBJ.Q><CONTENTS CTNID="QC-E-002425-19"><P>On 4&#xa0;June&#xa0;2019, the European Court of Auditors (ECA) published a special report on EU actions for cross-border healthcare. In its report, the ECA concluded that despite cooperation between the Member States having increased thanks to the EU’s cross-border healthcare measures, the benefits for patients are still limited. It therefore made recommendations focusing on the Commission’s support for National Contact Points to improve the provision of information, cross-border exchanges of health data and EU measures on rare diseases<NOTE TYPE="NUM"><P>https://www.eca.europa.eu/Lists/ECADocuments/SR19_07/SR_HEALTH_CARE_EN.pdf</P></NOTE>. </P><P><NO.P>1.</NO.P>Does the Commission acknowledge that EU cross-border healthcare measures need to be better managed by the Commission in order for the Cross-Border Healthcare Directive to be fully effective?</P><P><NO.P>2.</NO.P>Can it give a detailed reply to each of the three recommendations made by the ECA?</P><P><NO.P>3.</NO.P>What immediate, concrete action will it take in response to the ECA’s recommendations so as to ensure that EU patients benefit more from cross-border healthcare?</P></CONTENTS></QUESTION></AQE.QER>